A
Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
NASDAQ:AQST
Price:
2.75 USD
-2.14%
Market Closed
Updated:
Jun 10, 2024
Aquestive Therapeutics Inc
Total Liabilities
|
Aquestive Therapeutics Inc
Total Liabilities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Total Liabilities
$165.8m
|
CAGR 3-Years
13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Liabilities
$101.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Liabilities
$82.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
33%
|
CAGR 10-Years
16%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Liabilities
$128.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Liabilities
$65.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Liabilities
$51.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
See Also
What is Aquestive Therapeutics Inc's Total Liabilities?
Total Liabilities
165.8m
USD
165.8m
USD
Based on the financial report for Mar 31, 2024, Aquestive Therapeutics Inc's Total Liabilities amounts to 165.8m USD.
What is Aquestive Therapeutics Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
17%
17%
Over the last year, the Total Liabilities growth was -3%. The average annual Total Liabilities growth rates for Aquestive Therapeutics Inc have been 13% over the past three years , 17% over the past five years .
You don't have any saved screeners yet
